NO331228B1 - Anvendelse av en sammensetning som omfatter et ketotifensalt - Google Patents

Anvendelse av en sammensetning som omfatter et ketotifensalt

Info

Publication number
NO331228B1
NO331228B1 NO20020319A NO20020319A NO331228B1 NO 331228 B1 NO331228 B1 NO 331228B1 NO 20020319 A NO20020319 A NO 20020319A NO 20020319 A NO20020319 A NO 20020319A NO 331228 B1 NO331228 B1 NO 331228B1
Authority
NO
Norway
Prior art keywords
composition
ketotifen salt
ketotifen
salt
Prior art date
Application number
NO20020319A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020319D0 (no
NO20020319L (no
Inventor
Gyorgy Lajos Kis
Marcia Johanna Adam
Andrea Fetz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20020319D0 publication Critical patent/NO20020319D0/no
Publication of NO20020319L publication Critical patent/NO20020319L/no
Publication of NO331228B1 publication Critical patent/NO331228B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20020319A 1999-07-23 2002-01-21 Anvendelse av en sammensetning som omfatter et ketotifensalt NO331228B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114508 1999-07-23
PCT/EP2000/007030 WO2001007049A2 (en) 1999-07-23 2000-07-21 Ophthalmic composition comprising ketotifen

Publications (3)

Publication Number Publication Date
NO20020319D0 NO20020319D0 (no) 2002-01-21
NO20020319L NO20020319L (no) 2002-01-21
NO331228B1 true NO331228B1 (no) 2011-11-07

Family

ID=8238654

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020319A NO331228B1 (no) 1999-07-23 2002-01-21 Anvendelse av en sammensetning som omfatter et ketotifensalt

Country Status (20)

Country Link
US (2) US6777429B1 (cs)
EP (1) EP1198223A2 (cs)
JP (1) JP2003505419A (cs)
KR (1) KR20020012261A (cs)
CN (1) CN1358086A (cs)
BR (2) BR0012696A (cs)
CA (1) CA2377024A1 (cs)
CZ (1) CZ300614B6 (cs)
EE (1) EE05439B1 (cs)
HK (1) HK1046631A1 (cs)
HU (1) HU230738B1 (cs)
IL (1) IL146973A0 (cs)
MX (1) MXPA02000849A (cs)
NO (1) NO331228B1 (cs)
NZ (1) NZ516108A (cs)
PL (1) PL202496B1 (cs)
RU (1) RU2248789C2 (cs)
UA (1) UA74788C2 (cs)
WO (1) WO2001007049A2 (cs)
ZA (1) ZA200200425B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2002100436A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic once-a-day composition
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
KR20050092429A (ko) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
CA2585266C (en) * 2004-10-25 2010-10-19 Bausch & Lomb Incorporated Ophthalmic compositions and methods of using the same
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
EP2471507B1 (en) * 2006-09-29 2017-03-01 Johnson & Johnson Vision Care, Inc. Ophthalmic devices used in the treatment of ocular allergies
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
CN101808642B (zh) 2007-09-28 2012-05-02 布里格海姆妇女医院公司 肥大细胞稳定剂治疗肥胖症
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CA2754996A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (ja) 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
RU2003350C1 (ru) * 1991-03-01 1993-11-30 Институт иммунологии Способ лечени глюкокортикостероидзависимых атопических заболеваний
RU2007117C1 (ru) * 1992-03-20 1994-02-15 Юлия Михайловна Залесская Способ индивидуального подбора веществ для коррекции нарушений в организме
RU2108112C1 (ru) * 1993-04-16 1998-04-10 Вакамото Фармасьютикал Ко., Лтд. Водная лекарственная композиция, обладающая свойством обратимого терморегулируемого гелеобразования
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent

Also Published As

Publication number Publication date
EE05439B1 (et) 2011-08-15
EE200200040A (et) 2003-04-15
NO20020319D0 (no) 2002-01-21
KR20020012261A (ko) 2002-02-15
HU230738B1 (hu) 2018-01-29
MXPA02000849A (es) 2002-07-30
CA2377024A1 (en) 2001-02-01
NO20020319L (no) 2002-01-21
PL202496B1 (pl) 2009-06-30
HUP0202243A3 (en) 2006-03-28
HK1046631A1 (zh) 2003-01-24
US6777429B1 (en) 2004-08-17
EP1198223A2 (en) 2002-04-24
WO2001007049A2 (en) 2001-02-01
IL146973A0 (en) 2002-08-14
BRPI0017528A2 (pt) 2010-01-19
ZA200200425B (en) 2002-10-30
US6774137B2 (en) 2004-08-10
WO2001007049A3 (en) 2001-03-29
JP2003505419A (ja) 2003-02-12
NZ516108A (en) 2004-04-30
RU2248789C2 (ru) 2005-03-27
BRPI0017528B8 (pt) 2021-05-25
PL352382A1 (en) 2003-08-25
CN1358086A (zh) 2002-07-10
US20020183359A1 (en) 2002-12-05
BR0012696A (pt) 2002-04-09
CZ300614B6 (cs) 2009-07-01
BRPI0017528B1 (pt) 2017-06-13
HUP0202243A2 (hu) 2002-12-28
CZ2002243A3 (cs) 2002-04-17
UA74788C2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
NO331228B1 (no) Anvendelse av en sammensetning som omfatter et ketotifensalt
NO20015855D0 (no) Ny anvendelse av forbindelser som antibakterielle midler
DE60004317D1 (de) Salze von Sulfonium-Verbindungen
FI20010683L (fi) Nateglinidiä sisältävä koostumus
IS6024A (is) Ný efnasambönd
IS6239A (is) Ný efnasambönd
DE60041145D1 (de) Nutzung von daten
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1308108T3 (da) Tandbörste
ATE261679T1 (de) Zahnbürste
ATE264633T1 (de) Zahnbürste
DE10084428T1 (de) Zahnbürste
IS6139A (is) Ný efnasambönd
DE10190385T1 (de) Rotierende Zahnbürste
DE50009595D1 (de) Zahnbürste
DE50006709D1 (de) Zahnbürste
NO20001783D0 (no) Antigromidler som inneholder tiakloprid
IS6141A (is) Ný efnasambönd
FI19992609A7 (fi) Uusi koostumus
EE200100381A (et) Morfolinobensamiidi uued soolad
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
ID30381A (id) Penggunaan arilalkanoilpiridazina
DE50008657D1 (de) Verpackungsklebebänder
DE50012960D1 (de) Verpackungsklebebänder
SE9902902D0 (sv) New formulation

Legal Events

Date Code Title Description
MK1K Patent expired